 Connection
David Schwartz to Treatment Outcome
This is a "connection" page, showing publications David Schwartz has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.518 |
|
|
|
-
Schwartz DA. Top tips for endoscopic balloon dilation of Crohn's-related strictures (with video). Gastrointest Endosc. 2023 05; 97(5):974-976.
Score: 0.066
-
Levine M, Cantwell M, Postol K, Schwartz D. Comparison of a noncustom vs custom mandibular advancement device to treat obstructive sleep apnea. J Clin Sleep Med. 2023 01 01; 19(1):205-206.
Score: 0.066
-
Bennett AL, Schwartz DA. Endoscopic Evaluation and Management of Perianal Disease. Gastrointest Endosc Clin N Am. 2022 Oct; 32(4):747-759.
Score: 0.064
-
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022 05; 20(5):1059-1067.e9.
Score: 0.060
-
Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am. 2020 12; 49(4):671-688.
Score: 0.056
-
Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis. 2017 10; 23(10):1860-1866.
Score: 0.046
-
Malik S, Naqvi SAA, Shadali AH, Khan H, Christof M, Niu C, Schwartz DA, Adler DG. Fecal Microbiota Transplantation (FMT) and Clinical Outcomes Among Inflammatory Bowel Disease (IBD) Patients: An Umbrella Review. Dig Dis Sci. 2025 May; 70(5):1873-1896.
Score: 0.019
-
King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.
Score: 0.019
-
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024 08 09; 15(1):6822.
Score: 0.018
-
Diaz-Aguilar L, Stone LE, Soliman MAR, Padovano A, Ehresman J, Brown NJ, Produturi G, Battista M, Khan A, Pollina J, Amaral R, Abd-El-Barr MM, Moss I, Smith T, Deol GS, Lee BS, McMains MC, Joseph SA, Schwartz D, Pimenta L, Nguyen AD, Taylor WR. Radiographic alignment outcomes after the single-position prone transpsoas approach: a multi-institutional retrospective review of 363 cases. Neurosurg Focus. 2023 01; 54(1):E3.
Score: 0.016
-
Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor a Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci. 2022 07; 67(7):3129-3137.
Score: 0.015
-
Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, Horst SN, Schwartz DA, Adams DW, Freiberg MS, Gatskie V, King S, Abney LR, Beaulieu DB. Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. PLoS One. 2020; 15(3):e0230656.
Score: 0.014
-
Miller J, Chang T, Schwartz D, Peters M, Baum C. Outcomes of Adjuvant Radiotherapy Following Negative Surgical Margins for Cutaneous Squamous Cell Carcinoma. Dermatol Surg. 2019 09; 45(9):1111-1116.
Score: 0.013
-
Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Ghazi L, Patil SA, Quezada SM, Russman KM, Quinn CC, Jambaulikar G, Beaulieu DB, Horst S, Cross RK. Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. Dig Dis Sci. 2020 01; 65(1):96-103.
Score: 0.012
-
Weiner JP, Shao M, Schwartz D, Wong A, Schreiber D. Patterns of care and survival outcomes in the treatment of esophageal melanoma. Dis Esophagus. 2017 Feb 01; 30(2):1-6.
Score: 0.011
-
Alakailly X, Schwartz D, Alwanni N, Demko C, Altay MA, Kilinc Y, Baur DA, Quereshy F. Patient-centered quality of life measures after alloplastic temporomandibular joint replacement surgery. Int J Oral Maxillofac Surg. 2017 Feb; 46(2):204-207.
Score: 0.011
-
Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994 Apr; 149(4 Pt 1):893-8.
Score: 0.009
-
Dayton CS, Schwartz DA, Helmers RA, Pueringer RJ, Gilbert SR, Merchant RK, Hunninghake GW. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest. 1993 Jan; 103(1):69-73.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|